SUNPHARMA

When the Market Sells Everything Else, It Buys This | Sun Pharma

Tuesday's session told a clear story. Sensex fell 561 points to 77,054 and Nifty slipped below 24,100, as rising crude oil prices and escalating US-Iran tensions triggered broad-based selling. But one sector refused to follow the script. Nifty Pharma gained 1%, supported by buying in Sun Pharma and Dr. Reddy's, even as IT, realty, PSU banks and autos all declined. That defensive rotation is the story behind Sun Pharma today. Nifty Pharma has surged 14% in calendar year 2026, compared to just 6.7% for the Nifty 50 — a remarkable gap that reflects consistent outperformance over seven months. Sun Pharma sits at the centre of that run. FY26 revenue came in at Rs 58,462 crore — up 11.19% year on year — while net profit grew 5.04% to Rs 11,479 crore. Q4 FY26 saw 13.6% sales growth, with innovative medicines and the India business driving the gains, even as US generics faced some competitive pressure. The stock's 52-week range runs from Rs 1,548 to Rs 2,132, and Sun Pharma has already hit a 52-week high recently, rallying as much as 25% in a single month — a move few large-cap stocks on the Nifty have matched this year. 34 analysts maintain an average Buy rating with a 12-month consensus target of Rs 2,047.. On a day when global uncertainty keeps crude elevated and IT stocks under pressure, defensives like Sun Pharma tend to be where the market's smart money quietly parks itself.